Your Shopping Cart Is Empty
| Report Code: A10282 | Sep 2021 | Pages: 273 | ||
| Tables: 126 | Charts: 45 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Antimicrobial Susceptibility Testing Market
Request Now !The global antimicrobial susceptibility testing market was valued at $3,040.00 million in 2020, and is projected to reach $4,736.03 million by 2030, registering a CAGR of 5.8% from 2021 to 2030. Antimicrobial susceptibility testing (AST) is a method for detecting which antimicrobials a certain organism or group of organisms is susceptible to. Susceptibility occurs when microorganisms such as bacteria and fungi are unable to live in the presence of one or more antimicrobial medicines. It is a laboratory approach for evaluating which antimicrobial therapy is most efficient against microorganisms. It is used to evaluate which antimicrobial prevents the growth of bacteria, fungi, and other germs that cause illness. After microorganisms that cause infection, such as bacteria, fungi, and viruses, have been isolated in a culture of the specimen, susceptibility testing is performed on them.
Antimicrobial susceptibility testing (AST) is carried out to determine the possible efficacy of various antibiotics on bacteria and/or if bacteria have evolved resistance to specific antibiotics, as well as for antifungal and antiviral species. The results of this test can be used to help choose the drug(s) most likely to be helpful in treating an illness. They are able to obtain antibiotics.
AST assists in the evaluation of treatment services provided by hospitals, clinics, and national infectious disease control and prevention programs. The testing determines a bacterium's, fungi's, or viral strain's susceptibility to a panel of antibiotics, antifungals, and antivirals. The bacterium is exposed to these antimicrobials, and the test determines whether it will grow in their presence. This information is given to physicians in the form of the Minimum Inhibitory Concentration (MIC), which is a measure of a microorganism's susceptibility or resistance to an antibiotic.
The demand for antimicrobial susceptibility testing has been on a rise due to increasing prevalence of infectious disease epidemics such as Neisseria meningitides, Shigella, Neisseria gonorrhoeae, and Salmonella serotype typhi mainly due to lack of water supply, lack of sanitation and unhygienic conditions are also boosting demand for antimicrobial susceptibility testing kits. As a result, medical practitioners have realized the need of performing antibiotic susceptibility tests (ASTs), and they are now a required component of clinical microbiology laboratories and is anticipated to drive the market
In addition, over use and misuse in consumption of antibiotics leading to antimicrobial resistances (AMR), and increased use of antimicrobial susceptibility testing by biopharmaceutical, biotechnological, and pharmaceutical companies is a major factor for the significant growth of the antimicrobial susceptibility testing market, owing to a growing emphasis on drug discovery, the emergence of new diseases, as well as the increasing incidences of chronic disorders and the rising overall population is expected to propel the market growth of mouth ulcers treatment
Furthermore, the rising prevalence of hospital acquired infections (HAIs), a rise in patient population base (particularly in developing countries), and increased government awareness to combat antimicrobial resistance are likely to drive the market even further. Testing also aids in the evaluation of treatment services provided by hospitals, clinics, and national infectious disease control and prevention programs on a larger scale. As a result of changes in microbial genes, researchers have recently required to conduct continual monitoring operations for resistance patterns.
The antimicrobial susceptibility testing market is gaining interest from healthcare businesses due to an increase in demand for automated goods such as AST cards, AST panels, and high-tech automated systems that give higher accuracy, faster processing, and improved work flow. This leads to a rise in the use of automated systems in pharmaceutical and biotechnology firms, providing a huge potential for the industry to continue growing.
In addition, opportunities in untapped, emerging markets with high potential, due to improved healthcare infrastructure, increase in unmet healthcare needs and rise in prevalence of antimicrobial resistances in populations. Availability of various manual products, automated products providing results in less time with higher accuracy for testing’s is an emerging opportunity for the key players of the market to invest in the antimicrobial susceptibility testing market and thus will further accelerate the expansion of the market offering significant growth opportunities for the market during the forecast period.
The antimicrobial susceptibility testing market is segmented onto the basis of product type, method type, end user and region. On the basis of product type, the market is categorized into manual products, automated products and consumables. By method type the market is categorized into ETEST (Epsilometer test), disks diffusion, rapid automation method and others. By end user the market is categorized into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Depending on the product type manual product segment dominated the market in 2020, and is expected to continue this trend during the forecast period, due to increase in demand for manual products due to ease of availability, simple to use and its low cost as to that of automated products.
On the basis of method type, disk diffusion segment led the market in 2020, and is expected to retain its dominance during the forecast period, owing to its popularity because of simple to use and low costs.
By end user, hospitals and diagnostic laboratories exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
North America accounted for a majority of the global antimicrobial susceptibility testing market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of antibiotic resistance, presence of key players, increase in healthcare expenditure, advancements in technology and rise in government initiatives in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in overall population, and increased investments in healthcare sector in the region.
The key players operating in the global market include Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux SA, Bio-Rad Laboratories, Inc., Bruker, Danaher Corporation (Beckman Coulter), F. Hoffmann-La Roche AG, HiMedia Laboratories, Merck KGaA (MilliporeSigma), Thermo Fisher Scientific.
Key Benefits For Stakeholders
Key Market Segments
By Product Type
By Method Type
By End User
By Region
Key Market Players
Antimicrobial Susceptibility Testing Market Report Highlights
| Aspects | Details |
|---|---|
| By PRODUCT TYPE |
|
| By METHOD TYPE |
|
| By END USER |
|
| By Region |
|
| Key Market Players | MERCK KGAA (MILLIPORE SIGMA), ACCELERATE DIAGNOSTICS, INC., .BRUKER CORPORATION, HIMEDIA LABORATORIES, BECTON, DICKINSON, AND COMPANY, COMPAGNIE MERIEUX ALLIANCE SAS (BIOMERIEUX S.A.), .F. HOFFMANN-LA ROCHE AG, THERMO FISHER SCIENTIFIC, INC, BIO-RAD LABORATORIES, INC., DANAHER CORPORATION (BECKMAN COULTER INC.) |
CHAPTER 1:INTRODUCTION
1.1.Report description
Key benefits for stakeholders
1.2.Key market segments
1.3.Research methodology
1.3.1.Secondary research
1.3.2.Primary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rising incidence of infectious diseases coupled with epidemic & pandemic occurrences
3.5.1.2.Increasing adoption of antimicrobial susceptibility testing
3.5.1.3.Development of Manual and Automated Products
3.5.2.Restraint
3.5.2.1.High cost of automated AST systems & stringent government regulations
3.5.3.Opportunity
3.5.3.1.Awareness initiatives for antimicrobial resistance and its control
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the antimicrobial susceptibility testing market
CHAPTER 4:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Manual Products
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market analysis, by end user
4.3.Automated Products
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.3.4.Market analysis, by end user
4.4.Consumables
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.4.4.Market analysis, by end user
CHAPTER 5:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.ETEST
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Disks Diffusion
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Rapid Automation Method
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Others
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
CHAPTER 6:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals & Diagnostic Laboratories
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Pharmaceutical & Biotechnology Companies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Others
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America Antimicrobial susceptibility testing market, by Product Type
7.2.3.North America Antimicrobial susceptibility testing market, by Method Type
7.2.4.North America Antimicrobial susceptibility testing market, by End User
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. Antimicrobial susceptibility testing market, by Product Type
7.2.5.1.2.U.S. Antimicrobial susceptibility testing market, by Method Type
7.2.5.1.3.U.S. Antimicrobial susceptibility testing market, by End User
7.2.5.2.Canada
7.2.5.2.1.Canada Antimicrobial susceptibility testing market, by Product Type
7.2.5.2.2.Canada Antimicrobial susceptibility testing market, by Method Type
7.2.5.2.3.Canada Antimicrobial susceptibility testing market, by End User
7.2.5.3.Mexico
7.2.5.3.1.Mexico Antimicrobial susceptibility testing market, by Product Type
7.2.5.3.2.Mexico Antimicrobial susceptibility testing market, by Method Type
7.2.5.3.3.Mexico Antimicrobial susceptibility testing market, by End User
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe Antimicrobial susceptibility testing market, by Product Type
7.3.3.Europe Antimicrobial susceptibility testing market, by Method Type
7.3.4.Europe Antimicrobial susceptibility testing market, by End User
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany Antimicrobial susceptibility testing market, by Product Type
7.3.5.1.2.Germany Antimicrobial susceptibility testing market, by Method Type
7.3.5.1.3.Germany Antimicrobial susceptibility testing market, by End User
7.3.5.2.France
7.3.5.2.1.France Antimicrobial susceptibility testing market, by Product Type
7.3.5.2.2.France Antimicrobial susceptibility testing market, by Method Type
7.3.5.2.3.France Antimicrobial susceptibility testing market, by End User
7.3.5.3.UK
7.3.5.3.1.UK Antimicrobial susceptibility testing market, by Product Type
7.3.5.3.2.UK Antimicrobial susceptibility testing market, by Method Type
7.3.5.3.3.UK Antimicrobial susceptibility testing market, by End User
7.3.5.4.Italy
7.3.5.4.1.Italy Antimicrobial susceptibility testing market, by Product Type
7.3.5.4.2.Italy Antimicrobial susceptibility testing market, by Method Type
7.3.5.4.3.Italy Antimicrobial susceptibility testing market, by End User
7.3.5.5.Spain
7.3.5.5.1.Spain Antimicrobial susceptibility testing market, by Product Type
7.3.5.5.2.Spain Antimicrobial susceptibility testing market, by Method Type
7.3.5.5.3.Spain Antimicrobial susceptibility testing market, by End User
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe Antimicrobial susceptibility testing market, by Product Type
7.3.5.6.2.Rest of Europe Antimicrobial susceptibility testing market, by Method Type
7.3.5.6.3.Rest of Europe Antimicrobial susceptibility testing market, by End User
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Antimicrobial susceptibility testing market, by Product Type
7.4.3.Asia-Pacific Antimicrobial susceptibility testing market, by Method Type
7.4.4.Asia-Pacific Antimicrobial susceptibility testing market, by End User
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan Antimicrobial susceptibility testing market, by Product Type
7.4.5.1.2.Japan Antimicrobial susceptibility testing market, by Method Type
7.4.5.1.3.Japan Antimicrobial susceptibility testing market, by End User
7.4.5.2.China
7.4.5.2.1.China Antimicrobial susceptibility testing market, by Product Type
7.4.5.2.2.China Antimicrobial susceptibility testing market, by Method Type
7.4.5.2.3.China Antimicrobial susceptibility testing market, by End User
7.4.5.3.Australia
7.4.5.3.1.Australia Antimicrobial susceptibility testing market, by Product Type
7.4.5.3.2.Australia Antimicrobial susceptibility testing market, by Method Type
7.4.5.3.3.Australia Antimicrobial susceptibility testing market, by End User
7.4.5.4.India
7.4.5.4.1.India Antimicrobial susceptibility testing market, by Product Type
7.4.5.4.2.India Antimicrobial susceptibility testing market, by Method Type
7.4.5.4.3.India Antimicrobial susceptibility testing market, by End User
7.4.5.5.South Korea
7.4.5.5.1.South Korea Antimicrobial susceptibility testing market, by Product Type
7.4.5.5.2.South Korea Antimicrobial susceptibility testing market, by Method Type
7.4.5.5.3.South Korea Antimicrobial susceptibility testing market, by End User
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific Antimicrobial susceptibility testing market, by Product Type
7.4.5.6.2.Rest of Asia-Pacific Antimicrobial susceptibility testing market, by Method Type
7.4.5.6.3.Rest of Asia-Pacific Antimicrobial susceptibility testing market, by End User
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA Antimicrobial susceptibility testing market, by Product Type
7.5.3.LAMEA Antimicrobial susceptibility testing market, by Method Type
7.5.4.LAMEA Antimicrobial susceptibility testing market, by End User
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil Antimicrobial susceptibility testing market, by Product Type
7.5.5.1.2.Brazil Antimicrobial susceptibility testing market, by Method Type
7.5.5.1.3.Brazil Antimicrobial susceptibility testing market, by End User
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia Antimicrobial susceptibility testing market, by Product Type
7.5.5.2.2.Saudi Arabia Antimicrobial susceptibility testing market, by Method Type
7.5.5.2.3.Saudi Arabia Antimicrobial susceptibility testing market, by End User
7.5.5.3.South Africa
7.5.5.3.1.South Africa Antimicrobial susceptibility testing market, by Product Type
7.5.5.3.2.South Africa Antimicrobial susceptibility testing market, by Method Type
7.5.5.3.3.South Africa Antimicrobial susceptibility testing market, by End User
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA Antimicrobial susceptibility testing market, by Product Type
7.5.5.4.2.Rest of LAMEA Antimicrobial susceptibility testing market, by Method Type
7.5.5.4.3.Rest of LAMEA Antimicrobial susceptibility testing market, by End User
CHAPTER 8:COMPANY PROFILES
8.1.ACCELERATE DIAGNOSTICS, INC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.BECTON, DICKINSON, AND COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.BIO-RAD LABORATORIES, INC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.BRUKER CORPORATION
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.COMPAGNIE MERIEUX ALLIANCE SAS (BIOMERIEUX S.A.)
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Key strategic moves and developments
8.6.DANAHER CORPORATION (BECKMAN COULTER INC.)
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.F. HOFFMANN-LA ROCHE AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.HIMEDIA LABORATORIES
8.8.1.Company overview
8.8.2.Operating business segments
8.8.3.Product portfolio
8.9.MERCK KGAA (MILLIPORE SIGMA)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.THERMO FISHER SCIENTIFIC, INC.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 02.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR MANUAL PRODUCTS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR MANUAL PRODUCTS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 04.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AUTOMATED PRODUCTS, BY REGION, 2020-2030 ($MILLION)
TABLE 05.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AUTOMATED PRODUCTS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 06.CONSUMABLES SUSCEPTIBILITY TESTING MARKET FOR ANTIMICROBIAL, BY REGION, 2020-2030 ($MILLION)
TABLE 07.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONSUMABLES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 08.GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 09.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST, BY REGION, 2020-2030 ($MILLION)
TABLE 10.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISKS DIFFUSION, BY REGION, 2020-2030 ($MILLION)
TABLE 11.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RAPID AUTOMATION METHOD, BY REGION, 2020-2030 ($MILLION)
TABLE 12.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2020-2030 ($MILLION)
TABLE 15.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2030 ($MILLION)
TABLE 16.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 17.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21.NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 22.U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 23.U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 24.U.S. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 25.CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 26.CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 27.CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 28.MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 29.MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 30.MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 32.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 33.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34.EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 35.GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 36.GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 37.GERMANY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 38.FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 39.FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 40.FRANCE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 41.UK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 42.UK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 43.UK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 44.ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 45.ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 46.ITALY ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 47.SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 48.SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 49.SPAIN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 50.REST OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 52.REST OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56.ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 57.JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 58.JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 59.JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 60.CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 61.CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 62.CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 63.AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 65.AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 66.INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 67.INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 68.INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 71.SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 76.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 77.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78.LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 79.BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 80.BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 81.BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 82.SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 84.SAUDI ARABIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 85.SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 87.SOUTH AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 88.REST OF LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD TYPE, 2020-2030 ($MILLION)
TABLE 90.REST OF LAMEA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 91.ACCELERATE: COMPANY SNAPSHOT
TABLE 92.ACCELERATE: OPERATING SEGMENT
TABLE 93.ACCELERATE: PRODUCT PORTFOLIO
TABLE 94.ACCELERATE: KEY DEVELOPMENTS
TABLE 95.BD: COMPANY SNAPSHOT
TABLE 96.BD: OPERATING SEGMENTS
TABLE 97.BD: PRODUCT PORTFOLIO
TABLE 98.BD: KEY DEVELOPMENTS
TABLE 99.BIORAD: COMPANY SNAPSHOT
TABLE 100.BIORAD: OPERATING SEGMENTS
TABLE 101.BIORAD: PRODUCT PORTFOLIO
TABLE 102.BRUKER: SNAPSHOT
TABLE 103.BRUKER: OPERATING SEGMENTS
TABLE 104.BRUKER: PRODUCT PORTFOLIO
TABLE 105.COMPAGNIE: COMPANY SNAPSHOT
TABLE 106.COMPAGNIE: OPERATING SEGMENT
TABLE 107.COMPAGNIE: PRODUCT PORTFOLIO
TABLE 108.COMPAGNIE: KEY DEVELOPMENTS
TABLE 109.DANAHER: COMPANY SNAPSHOT
TABLE 110.DANAHER: PRODUCT SEGMENTS
TABLE 111.DANAHER: PRODUCT PORTFOLIO
TABLE 112.DANAHER: KEY DEVELOPMENTS
TABLE 113.ROCHE: COMPANY SNAPSHOT
TABLE 114.ROCHE: PRODUCT SEGMENTS
TABLE 115.ROCHE: PRODUCT PORTFOLIO
TABLE 116.ROCHE: KEY DEVELOPMENTS
TABLE 117.HIMEDIA: COMPANY SNAPSHOT
TABLE 118.HIMEDIA: OPERATING SEGMENTS
TABLE 119.HIMEDIA: PRODUCT PORTFOLIO
TABLE 120.MERCK: COMPANY SNAPSHOT
TABLE 121.MERCK: OPERATING SEGMENTS
TABLE 122.MERCK: PRODUCT PORTFOLIO
TABLE 123.THERMO FISHER: COMPANY SNAPSHOT
TABLE 124.THERMO FISHER: OPERATING SEGMENTS
TABLE 125.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 126.THERMOFISHER: KEY DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2020
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF MANUAL PRODUCTS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AUTOMATED PRODUCTS, BY COUNTRY, 2020-2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST, BY COUNTRY, 2020-2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISK DIFFUSION, BY COUNTRY, 2020-2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RAPID AUTOMATION METHOD, BY COUNTRY, 2020-2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 23.ACCELERATE: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.ACCELERATE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25.BD: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.BD: REVENUE SHARE BY REGION, 2020(%)
FIGURE 28.BIORAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.BIORAD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.BIORAD: REVENUE SHARE BY REGION, 2020(%)
FIGURE 31.BRUKER: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.BRUKER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.BRUKER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34.DANAHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.DANAHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.ROCHE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42.MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 43.THERMO FISHER: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
This section provides the opinions of the top level CXOs in the antimicrobial susceptibility testing market. According to the insights of CXOs, increasing prevalence of antimicrobial resistance, due to overuse and misuse of antimicrobials, rise in susceptibility testing in hospitals and clinical laboratories, are all attributed for growth of the antimicrobial susceptibility testing market.
The CXOs further added that rise in infectious diseases like tuberculosis, typhoid, cholera, pneumonia and others, surge in occurrences of epidemics and pandemics the current ongoing COVID-19 are also increasing demand for antimicrobial susceptibility testing kits. As a result, medical practitioners have recognized the significance of performing antimicrobial susceptibility tests (ASTs), and it is now an essential component of clinical microbiology laboratories.
In addition, the increasing incidence of hospital acquired infections (HAIs), surge in patient population base (especially in developing countries), rising awareness by the government to combat antimicrobial resistance is expected to further boost the market.
The antimicrobial susceptibility testing market gains interest of healthcare companies, owing to surge in demand for automated products like the AST cards, AST panels and high tech automated systems that provide higher accuracy, high speed and better work flow at the same time. This leads to increase in adoption of automated systems in pharmaceutical and biotechnological companies thus is a great opportunity for further propelling the growth of the market.
North America is expected to witness highest growth, in terms of revenue, owing to rise in prevalence of infectious diseases, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to increase in infectious diseases, rise in the number of patient population, increasing awareness in healthcare sectors. However, high cost of the automated systems and stringent government policies may restrain the market growth during the forecast period.
A. The total market value of antimicrobial susceptibility testing market is $3,040.0 million in 2020.
A. The forcast period for antimicrobial susceptibility testing market is 2021 to 2030
A. The market value of antimicrobial susceptibility testing market in 2021 is $2,851.52 million.
A. The base year is 2020 in antimicrobial susceptibility testing market
A. Top companies such as Accelerate Diagnostics, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc.,Bruker Corporation, Campaigne (Biomérieux SA), Danaher Corporation (Beckman Coulter), F. Hoffmann-La Roche AG, HiMedia Laboratories.,Merck KGaA (MilliporeSigma), Thermo Fisher Scientific Inc. held a high market position in 2020.
A. Manual products segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period. The manual products like susceptibility disks, plates, MIC strips used for testing are easily available, simple to use and come at an affordable cost.
A. Rise in incidences of various infectious diseases like tuberculosis, pnemonia, typhoid, emergence of new diseases due to gene mutations, overuse and misuse of antimicrobials leading to antimicrobial resistance (AMR) is among the key drivers propelling growth of antimicrobial susceptibility testing market globally. Furthermore, rising prevalence of testings in hospitals and diagnostics for providing appropriate therapies to patient would further push the industry growth.
A. North America is projected to account for a major share of the global antimicrobial susceptibility testing market during the forecast period. U.S. dominated the North America antimicrobial susceptibility testing market owing to increased infectious diseases and rise in national initiatives to combat antimicrobial resistance across the country.
Start reading instantly.
This Report and over 68,245+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report